BEVERLY, MA--(Marketwire - February 03, 2010) - INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today reported results from a study of the INVOcell procedure for the treatment of infertility being conducted by the CECOLFES Center of Fertility and Sterility located in Bogota, Colombia. The 50 patient study was presented at the annual Salvador Society of Endoscopy and Reproduction Symposium dedicated to the INVO technology. The study’s purpose was to determine the pregnancy rate of INVO in infertile couples with the primary endpoint being clinical pregnancy (fetal heartbeat at seven weeks). The Study had a 36% clinical pregnancy rate, which is equivalent to current techniques available today; additionally, the results showed only a 6% multiple pregnancy rate, which is a significant decrease from traditional procedures’ multiple pregnancy rate. The full details are expected to be published in a peer review journal in the next few months.
Over 100 physicians attended the conference from all over Central and South America. Dr. Rene Frydman, the first physician to have a baby born through IVF in France and the second in all of Europe, presented on mild ovarian stimulation. Mild stimulation is used in the INVO procedure.
INVO Bioscience CEO Katie Karloff stated, “The 36% pregnancy rate in this study of 50 infertile couples provides critical market data on the INVOcell needed to expand the INVO procedure throughout the world as a procedure that is not only cost effective but also has an efficacy comparable to today’s procedures in real world applications.”
Last, management has received several inquiries over the last several weeks questioning whether members of management have been selling shares of INVO stock. Since the Company became public on December 6, 2009, the directors and officers of the Company have sold only 30,000 shares of the 31.3 million shares they hold. The officers have not taken salaries in the past year in order to preserve cash; however, the Company continues to accrue the unpaid salaries.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Kathleen Karloff
INVO Bioscience, Inc.
978-878-9505 x505
www.invobioscience.com
